Pharmacokinetics of tedizolid following oral administration: Single and multiple dose, effect of food, and comparison of two solid forms of the prodrug

Pharmacotherapy

Volumn 34, Issue 3, 2014, Pages 240-250

  Flanagan, Shawn D ^a   Bien, Paul A ^a   Muñoz, Kelly A ^a   Minassian, Sonia L ^b   Prokocimer, Philippe G ^a  

^a Trius Therapeutics   (United States)

^b Minassian Biostatistics Inc   (United States)

Author keywords

Food effect; Pharmacokinetics; Relative bioavailability; Tedizolid phosphate disodium; Tedizolid phosphate free acid; TR 700; TR 701; TR 701 FA

Indexed keywords

ALANINE AMINOTRANSFERASE; LINEZOLID; PLACEBO; TEDIZOLID;

ADULT; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CONFERENCE PAPER; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; ETHNICITY; FEMALE; FOOD DRUG INTERACTION; HUMAN; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SINGLE DRUG DOSE; STEADY STATE;

FOOD EFFECT; PHARMACOKINETICS; RELATIVE BIOAVAILABILITY; TEDIZOLID PHOSPHATE DISODIUM; TEDIZOLID PHOSPHATE FREE ACID; TR-700; TR-701; TR-701 FA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHATES; OXAZOLES; PRODRUGS; YOUNG ADULT;

EID: 84892166007     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1337     Document Type: Conference Paper

References (34)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339: 520-32.
2. Gerber JS, Coffin SE, Smathers SA, et al. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis 2009;49: 65-71.
3. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010;65(Suppl 3): 35-44.
4. Pfizer. Zyvox (linezolid) Prescribing Information (Revised May 2013). Available from http://labeling.pfizer.com/ShowLabeling. aspx?id=649. Accessed July 08, 2013.
5. Ager S, Gould K. Clinical update on linezolid in the treatment of gram-positive bacterial infections. Infect Drug Resist 2012;5: 87-102.
6. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiological characteristics cannot distinguish communityassociated methicillin-resistant Staphylococcus aureus infection from methicillin- susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007;44: 471-82. (Pubitemid 46233247)
7. Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother 2010;65: 24-36.
8. Stefani S, Goglio A. Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance. Int J Infect Dis 2010;14(Suppl 4):S19-22.
9. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54: 755-71.
10. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358: 207-8. (Pubitemid 32718546)
11. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004;39: 1010-5. (Pubitemid 39313459)
12. Peeters MJ, Sarria JC. Clinical characteristics of linezolidresistant Staphylococcus aureus infections. Am J Med Sci 2005;330: 102-4. (Pubitemid 41140465)
13. Flamm RK, Farrell DJ, Mendes RE, et al. LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis 2012;74: 54-61.
14. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009;53: 3236-9.
15. Im WB, Choi SH, Park JY, et al. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem 2011;46: 1027-39.
16. Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR- 700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008;52: 4442-7.
17. Livermore DM, Mushtaq S, Warner M, et al. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009;63: 713-5.
18. Rodríguez-Avial I, Culebras E, Betriu C, et al. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67: 167-9.
19. Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009;53: 5265-74.
20. Louie A, Liu W, Kulawy R, et al. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin- susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011;55: 3453-60.
21. Keel RA, Tessier PR, Crandon JL, et al. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother 2012;56: 4403-7.
22. Drusano GL, Liu W, Kulawy R, et al. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011;55: 5300-5.
23. Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother 2012;56: 4713-7.
24. Tessier PR, Keel RA, Hagihara M, et al. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother 2012;56: 2342-6.
25. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother 2012;56: 2627-34.
26. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents 2012;40: 51-4.
27. Dreskin H, Boyea T, Barker J, Fang E, Prokocimer P. An evaluation of the absorption, metabolism, and excretion of orally administered [14C]-TR-701 FA in healthy subjects. [abstract A2-033]. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
28. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011;55: 583-92.
29. Prokocimer P, Bien P, de Anda C, et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against grampositive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56: 4608-13.
30. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate versus linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309: 559-69.
31. Bien P, Prokocimer P, Munoz KA, et al. Absolute bioavailability and pharmacokinetics after single and multiple intravenous administration in healthy adult subjects [abstract A1-013]. Presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA.
32. Antal EJ, Grasela T, Bergstrom T, et al. The role of population PK/PD analysis during the implementation of a bridging strategy for linezolid, in 36th Drug Information Association Meeting; Hong Kong, November 16-19, 2000. Drug Information Association (DIA), Horsham, PA.
33. Meagher AK, Forrest A, Rayner CR, et al. Population pharmacokinetics of linezolid in patients treated in a compassionate- use program. Antimicrob Agents Chemother 2003;47: 548-53. (Pubitemid 36158080)
34. Plock N, Buerger C, Joukhadar C, et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos 2007;35: 1816-23. (Pubitemid 47481573)